12 stories mentioning ASX:AVRUpdated 7d ago
Every FINWIRES story that references ASX:AVR, newest first.
Anteris Technologies (ASX:AVR) said Brent Moen was appointed as chief financial officer, effective Sept. 11, succeeding Matthew McDonnell, according to a Monday Australian bourse filing.Moen previously served as CFO of LifeLens Technologies, per the filing.The medical technology company's shares rose nearly 4% in recent trading on Monday.
Anteris Technologies (ASX:AVR) logged a $0.30 loss per share for the second quarter, compared with a $0.58 loss per share a year ago, a Wednesday filing showed.For the three months ended June 30, net sales reached $1 million versus $618,000 previously, the Australia-listed medical technology company added.
Anteris Technologies (ASX:AVR) said the Federal Court of Australia granted relief over the late lodgment of a cleansing notice due to an administrative oversight, extending the filing deadline to July 31 and validating 44,068 chess depositary interests issued on July 10, according to an Australian bourse filing on Monday after market hours.The Court also confirmed the validity of the related trades, exempted affected holders from potential civil liability, and directed the company to notify regulators and investors while publishing the Court's orders, per the filing.The company has requested that the Australian Securities Exchange lift the trading halt on its securities, with trading set to resume at market open on Tuesday, the filing added.
Here are the ASX-listed companies with the biggest gains on Wednesday.Wisetech Global (ASX:WTC): +13%, AU$32.51BCI Minerals (ASX:BCI): +11%, AU$0.42Anteris Technologies (ASX:AVR): +10%, AU$14.99Xero (ASX:XRO): +8%, AU$70.31Telix Pharmaceuticals (ASX:TLX): +7%, AU$15.54Neuren Pharmaceuticals (ASX:NEU): +5%, AU$12.99Tasmea (ASX:TEA): +5%, AU$9.45Lindian Resources (ASX:LIN): +5%, AU$0.92Regis Healthcare (ASX:REG): +4%, AU$6.53Iluka Resources (ASX:ILU): +4%, AU$7.54
(Updates to add tickers)Here are the ASX-listed companies with the biggest losses on Friday:Energy Resources of Australia (ASX:ERA): -20%, AU$0.002United Overseas Australia (ASX:UOS): -6%, AU$0.68Tamboran Resources (ASX:TBN): -7%, AU$0.22REA Group (ASX:REA): -4%, AU$141.51News Corp (ASX:NWS): -4%, AU$42.45Viva Energy Group (ASX:VEA): -4%, AU$2.24DigiCo Infrastructure REIT (ASX:DGT): -4%, AU$2.43Tuas (ASX:TUA): -3%, AU$2.62Anteris Technologies Global (ASX:AVR): -3%, AU$13.08Beach Energy (ASX:BPT): -2%, AU$1.06
(Updates to add stock movement in the headline and last paragraph)Anteris Technologies (ASX:AVR) received authorization from France's National Agency for Medicines and Health Products Safety to begin patient recruitment in its Paradigm pivotal trial of the DurAVR transcatheter heart valve for severe calcific aortic stenosis, according to a Monday statement by the company.Calcific aortic stenosis is a condition where the aortic valve of the heart narrows or is blocked due to calcium buildup.The Paradigm trial is a prospective randomized controlled study assessing the safety and efficacy of the DurAVR transcatheter heart valve versus commercially available transcatheter aortic valve replacement systems.The clearance allows enrollment at leading French clinical centers, the company said.The company's shares fell around 6% in recent Tuesday trade.
Anteris Technologies (ASX:AVR) received authorization from France's National Agency for Medicines and Health Products Safety to begin patient recruitment in its Paradigm pivotal trial of the DurAVR transcatheter heart valve for severe calcific aortic stenosis, according to a Monday statement by the company.Calcific aortic stenosis is a condition where the aortic valve of the heart narrows or is blocked due to calcium buildup.The Paradigm trial is a prospective randomized controlled study assessing the safety and efficacy of the DurAVR transcatheter heart valve versus commercially available transcatheter aortic valve replacement systems.The clearance allows enrollment at leading French clinical centers, the company said.
Anteris Technologies (ASX:AVR) reported Wednesday first quarter loss of $0.28 per share, compared with $0.61 a year earlier.Analysts polled by FactSet expected a loss of $0.27 per share.Net sales for the three months ended March 31 was $494,000, compared with $556,000 a year earlier. Analysts surveyed by FactSet expected sales revenue of $800,000.
Anteris Technologies (ASX:AVR) has enrolled and successfully treated the first US patients in its PARADIGM global pivotal trial of the DurAVR transcatheter heart valve for severe calcific aortic stenosis, according to a Wednesday Australian bourse filing.The procedures were carried out at Montefiore Medical Center in New York, the filing added.The company's shares rose 6% in recent Wednesday trade.
Anteris Technologies (ASX:AVR) said it has notified v2vmedtech of its election to discontinue additional development contributions under a contribution and stock purchase agreement dated April 18, 2023, triggering a break fee of $400,000 payable to v2v, according to a Thursday Australian bourse filing.The company said following the notice, it has no further obligation to make additional development contributions, while the initial shareholders of v2v have the right to either acquire all of the company's equity interest in v2v for an amount equal to its aggregate contributions to date, or reduce the company's equity interest to a capped minority ownership percentage.v2v has not informed the company as to which option it plans to pursue, the filing added.The development agreement between the parties will terminate upon payment of the $400,000 break fee, with the company not expecting the discontinuation to have a materially adverse effect on its financial position or liquidity, the company added.The company's shares rose 3% in recent Thursday trade.
Anteris Technologies (ASX:AVR) said it has secured US Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services (CMS) national coverage policy, according to a Wednesday Australian bourse filing.The PARADIGM Trial is evaluating the safety and effectiveness of the DurAVR transcatheter heart valve (THV) compared to transcatheter aortic valve replacements (TAVRs), with DurAVR THV being Anteris' product to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve, the filing added.The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation.The company said that securing this reimbursement eligibility is expected to facilitate US site activation and accelerate operational momentum across participating centers.The company's shares rose 2% in recent Wednesday trade.
Anteris Technologies Global's (ASX:AVR) wholly-owned unit, Anteris Technologies, entered into a lease agreement with Northcross West Industrial Owner for around 181,436 square feet of space in an office and warehouse facility in Brooklyn Park, Minnesota, according to a Friday Australian bourse filing.The initial term of the lease starts on Sept. 1 and expires on Aug. 31, 2037, and may be extended for two periods of 84 months each at market rent, subject to certain terms and conditions.Anteris will pay a monthly minimum rent initially of roughly $152,709, subject to contractual rent abatements, annual escalations, and other adjustments as well as real estate taxes, operating expenses, and other charges.
